| Hosting Organization |
 |
 |
| Operating Organization |

Foreign Experts Databank
of SAFEA-Dalian Biotechnological and Medical Experts Subdivision
BIT Lifesciences, Inc. |
| Supporting Organization |
 |
| International Marketing Partner |
 |
|
Participants List
(Academia) |
National Yang-Ming University, Taiwan
Abyad Medical Center and Middle-East Longevity Institute, Lebanon
Akershus University Hospital, Norway
Aligarh M University, India
American University of Beirut, USA
Antwerp University Hospital, Belgium
Applied Proteomics and Molecular Medicine, USA
Aristotelian University of Thessaloniki, Greece
Banaras Hindu University, India
Barrow Neurological Institute, USA
Baylor College of Medicine, USA
Ben-Gurion University of the Negev, Israel
Boston University School of Medicine, USA
Cancer Research Technology, UK
CHDI Foundation, California
Chinese Academy of Sciences, China
CRG-Centre de Regulaci Genmica, Spain
CSIRO Molecular and Health Technologies, Australia
Duke University, USA
Emory University, USA
exas Southern University, USA
Florida A&M University, USA
Global Pathology Support, The Netherlands
Gujarat AIDS Awareness and Prevention Unit, India
Haematopoietic Stem Cell Laboratory, UK
Harvard Medical School, USA
Hospital S Hospital S Joao, Portugal
Human BioMolecular Re-. search Institute, USA
Indiana University School of Medicine, USA
Indiana University School of Medicine, USA
Innsbruck Medical University, Austria
Institute of Experimental Pharmacology, Slovak
Instituto De Biologia Experimentale Tecnologica, Portugal
Karolinska Institutet, Sweden
Keystone College Academia, USA
McGill University, Canada
Mercer University, USA
National Center for Toxicological Research, USA
National Institutes of Health, USA
Netherlands Cancer Institute, The Netherlands
New York Medical College, USA
Osaka University, Japan
Paul-Ehrlich-Institute, Germany
Penn State College of Medicine, USA
Pennsylvania State University College of Medicine, USA
Pharmacology Temple University, USA
Scientific Advisory Board Tolerx, USA
Shanghai Unviversity of Traditional Chinese Medicine, China
Solid Tumor Working Party, Italy
Stanford University, USA
Structural Genomics Consortium Karolinska Institutet, Sweden
Tabriz University of Medical Sciences, Iran
Technion - Israel Institute of Technology Rappaport Institute, Israel
The Babraham Institute, UK
The Hebrew University, Israel
The Institute of Cancer Research, UK
The University of Queensland, Australia
The University of Sydney, Australia
The University of Texas, USA
UC College of Medicine, USA
Universidade Federal Fluminense, Brazil
University Clinic Bonn, Germany
University of Basel, Switzerland
University of British Columbia, Canada
University of California, USA
University of California-San Francisco, USA
University of Camerino, Italy
University of Cape Town, USA
University of Colorado Health Sciences Center, USA
University of Crete, Greece
University of Geneva, Switzerland
University of Heidelberg, Germany
University of Hong Kong, China
University of Maryland School of Pharmacy, USA
University of Maryland, USA
University of Massachusetts Medical School, USA
University of Miami School of Medicine, USA
University of Miami, USA
University of Miami, USA
University of Oklahoma Health Sciences Center, USA
University of Siena, Italy
University of Southern Denmark, Denmark
University of Texas at Dallas, USA
University of Texas Health Science Center, USA
University of Texas Medical, USA
University of the Sciences in Philadelphia, USA
University of Utah School of Medicine, USA
University of Western Australia, Australia
Utah State University, USA
Virginia Commonwealth University, USA
University of Gothenburg, Sweden
|
Participants List
(Business) |
3 P Biopharmaceuticals, USA
Abbott Laboratories, USA
Adolor Corporation, USA
Affimed Therapeutics AG, Germany
AILERON Therapeutics, USA
Algorithme Pharma Inc., Canada
Allon Therapeutics Inc., USA
Alpha Cancer Technologies Inc., USA
Alpha-2 Pharmaceutica AB, Israel
Amgen, Inc., USA
Arena Pharmaceuticals, USA
Astellas Pharma Inc, Japan
Astellas Pharmaceutical Inc., Japan
AstraZeneca Pharmaceuticals, USA
AstraZeneca R&D Molndal, Sweden
Astrazeneca R&D Sodertolje, Sweden
AstraZeneca, UK
AstraZeneca, USA
AuxoCell Laboratories, Inc., USA
Avexa Ltd, Australia
Bayer HealthCare, USA
Bayer Schering Pharma AG, Germany
BellBrook Labs, LLC, USA
Biological Mimetics, Inc., USA
BioPerspectives, USA
Biota Holdings Limited, USA
Boehringer Ingelheim Pharmaceuticals, Inc., USA
Bristol-Myers Squibbs, USA
Centocor/Johnson & Johnson, USA
Chemistry Forma Therapeutics, Inc., Singapore
Coley Pharmaceutical GmbH, Germany
Cordex Pharma, Inc., USA
Cornerstone Pharmaceuticals, USA
Covidien, USA
Daiichi Sankyo Pharma Development, Japan
deCODE Chemistry, USA
DxS Ltd, USA
Eisai Co., Ltd., Japan
Elan Pharmaceuticals, USA
Europe GlaxoSmithKline R&D, UK
Genentech, USA
Genetix Ltd, UK
genscript, USA
Genzyme Pharmaceuticals, USA
Gilead Sciences Benzothiadiazine Hepatitis C NS5B, USA
Hoffmann-La Roche, Switzerland
ICON PLC, USA
IDDC Corporation, USA
Idera Pharmaceuticals, USA
Jesus College, England
Johnson & Johnson Pharmaceutical, USA
Johnson & Johnson Research Pty Limited, Australia
Laboratory Cellular Technology Ltd., USA
Lundbeck Research, USA
Mallinckrodt, Inc., USA
MDS Pharma Services, USA
Medimmune, UK
Merck & Co. Inc, USA
Merck & Co., Italy
Merck and Co., Inc., China
Merck KGaA, Germany
Merck Research Laboratories, USA
Nerviano Medical Sciences, Italy
Novartis Institutes for Biomedical Research, USA
Novartis Institutes, Switzerland
Novartis Pharmaceuticals Corporation, USA
Novartis, China
Ocimum Biosolutions, India
Ondokuz Mayis University, Turkey
OphthalmoPharma, Switzerland
Pfizer, USA
Pharmanet Development Group, Inc., USA
PharmaNet, Inc., USA
Ranbaxy Laboratories Limited, India
Reaction Biology Corporation, USA
RegPak BioPharma Consulting, The Netherlands
Sanofi Aventis, USA
Schering Plough Research Institute, USA
Schlich & Co, UK
Scott & White, USA
Sequoia Pharmaceuticals Inc., USA
SeraCare Life Sciences, USA
Shanghai Biochip Co., Ltd, China
Shenogen Pharma Group, China
Siena Biotech S.p.A. A company, USA
Simulations Plus, Inc., USA
Synta Pharmaceuticals Corp, USA
TEVA Pharmaceuticals, USA
The Takeda Oncology Company, USA
ThromboGenics, USA
Transgene, France
US Oncology Research, Inc., USA
Vaxinnate, USA
Wyeth Research, USA
XOMA (US) LLC, USA
Zeptosens C a Division of Bayer (Schweiz) AG, Switzerland
Zhejiang Hisun Pharmaceutical Co., Ltd, China
Tehran University of Medical Sciences , Iran
|
|
 |
|
 |
WCG 2009
(December 1-7, 2009, Foshan, China) |
 |
ICC 2009
(Dec. 5-7, 2009, Shanghai, China) |
 |
ICA 2010
(March 24-26, 2010, Beijing, China) |
 |
WCV 2010
(March 24-26, 2010, Beijing, China) |
 |
SEB 2010
(Apr. 22-24, 2010, Shanghai, China) |
|
|
|
| Schedule |
|
|
IDDST 2009 is comprised of Eight Section s designed to offer comprehensive sessions that address current issues in Drug R&D and innovative therapeutics. You can register a whole conference or select a single Section or register for special service package that you want for your participation. Now the program is under developing from viewing submitted abstracts.
Chapter 1: Basic Sciences of Preclinical Studies
-Sciences is All We Need to Start
Chapter 2: Smart Drug Discovery Chemistry
-Applied Robust Chemistry to Better Molecules
Chapter 3: Methodology & Innovative tools for drug discovery, Drug delivery and Drug Development
-Master the Matured Cutting-Edge Technologies for Drug Innovations
Chapter 4: Translational Medicine
-Bridge Pharm R & D from Bench to Bedside
Chapter 5: Drug Discovery of Major Diseases
-Targeting Unsolved Life Threatening Diseases
Chapter 6: New Heats for Biotherapeutics
-Discover Humanized Natural Bio-Drugs
Chapter 7: Milestones of Novel Therapeutics Pipeline
-Update and Case Studies for Novel INDs on Trials
Chapter 8: Outsourcing, Partnership, and Licensing across the World
- Cost Effective and Result Driving Forces
Program Schedule
Time: October 22-25 Venue: Everbright Convention and Exhibition Center , Shanghai , China
Time |
Program |
Place |
October 21, 2009 (Wednesday)
08:00-20:00 |
Registration |
Lobby, 1F, ECEC |
October 22, 2009 (Thursday)
08:20-08:40 |
Group Photo |
The Gate of ECEC, 1F |
October 22, 2009 (Thursday)
09:00-09:35 |
Opening Ceremony |
Grand Ball, 2F, ECEC |
October 22, 2009 (Thursday)
09:40-11:45 |
Keynote Forum |
October 22, 2009 (Thursday)
18:30-20:30 |
Welcome Banquet and Art Performance (Sponsored by Roche) |
|
October 22, 2009 (Thursday) Afternoon |
13:30-17:50 |
Section 1-1: Oncology and Drug Discovery |
Room No. 9, 2F, ECEC |
15:05-17:35 |
Section 1-2: Inflammation and Drug Discovery |
Room No. 16, 2F, ECEC |
13:30-17:30 |
Section 2-1: Receptors and Ion Channel Based Drug Design and Development |
Room No. 18, 2F, ECEC |
13:30-16:45 |
Section 2-2: Fragment Based Drug Design and Development |
Room No. 20, 2F, ECEC |
13:30-16:50 |
Section 3-1: Functional Genomics, Proteomics, Metabolomics, System Biology for Drug Discovery |
Room No. 11, 2F, ECEC |
13:30-16:50 |
Section 3-2: Molecular Target and Biomarkers for Drug Discovery |
Room No. 12, 2F, ECEC |
13:30-17:50 |
Section 3-13: Current Strategies of Bioequivalence & Bioavailability in Drug Development (Sponsored by OMICS Publishing Group) |
Room No.8, 2F, ECEC |
13:30-14:45 |
Section 4-1: Translational Biomedicine and Multiplex Assays for the Progress of Translational Medicine |
Room No. 16, 2F, ECEC |
13:30-17:10 |
Section 5-1: Anticancer Drug Discovery (Part I) |
Room No. 7, 2F, ECEC |
October 23, 2009 (Friday) Morning |
08:10-12:30 |
Section 1-3: Endocrinology and Drug Discovery |
Room No. 7, 2F, ECEC |
08:30-11:45 |
Section 1-4: Immunology and Drug Discovery |
Room No. 11, 2F, ECEC |
08:10-10:10 |
Section 2-3: RNA/DNA Structure-Based Drug Discovery Chemistry |
Room No. 12, 2F, ECEC |
08:30-11:50 |
Section 2-4: Computer Aided Drug Design and SAR Studies |
Room No. 16, 2F, ECEC |
10:30-12:10 |
Section 3-3: Biochips, Microarray and Molecular Imaging for Drug Discovery |
Room No. 12, 2F, ECEC |
08:10-10:10 |
Section 3-4: Bioinformatics/Chemoinformatics and Bio-IT/Pharm-IT for Drug Discovery |
Room No. 9, 2F, ECEC |
08:30-11:50 |
Section 4-2: Translational Medicine from Biomarkers, Molecular Profiling to Clinical Trials |
Room No. 20, 2F, ECEC |
10:30-12:10 |
Section 5-3: Anti-Neurodegenerative Drug Discovery |
Room No. 9, 2F, ECEC |
08:30-11:45 |
Section 5-4: Cardiovascular & Pulmonary Diseases and Drug Discovery |
Room No. 18, 2F, ECEC |
08:30-12:10 |
Section 6-2: Monoclonal Antibody Based Biotherapeutics |
Room No. 8, 2F, ECEC |
October 23, 2009 (Friday) Afternoon |
13:30-15:10 |
Section 1-5: Pharmacology, PK/PD and Drug Discovery |
Room No. 8, 2F, ECEC |
15:30-17:30 |
Section 1-6: Toxicology and Drug Discovery |
Room No. 18, 2F, ECEC |
13:30-15:10 |
Section 2-5: Virtual Screening to Combinatorial Chemistry for Hit Findings |
Room No. 12, 2F, ECEC |
13:30-16:45 |
Section 2-6: Structure Biology Based Drug Design and Synthesis |
Room No. 7, 2F, ECEC |
15:30-17:00 |
Section 3-5: RNAi, microRNA, and Non-Coding RNA Technologies |
Room No. 12, 2F, ECEC |
13:30-17:10 |
Section 3-12: Pharmaceutical Analysis and Quality |
Room No. 11, 2F, ECEC |
15:30-17:30 |
Section 5-5: Anti-inflammation and Anti-autoimmune Diseases Drug Discovery |
Room No. 8, 2F, ECEC |
13:30-17:10 |
Section 6-1: Protein Based Biotherapeutics |
Room No. 16, 2F, ECEC |
15:30-17:00 |
Section 6-3: Gene Therapeutics R & D |
Room No. 20, 2F, ECEC |
13:10-15:10 |
Section 7-1: Anticancer Pipeline Therapeutics |
Room No. 18, 2F, ECEC |
13:30-15:10 |
Section 8-2: Services in Biological Sciences |
Room No. 20, 2F, ECEC |
13:30-17:10 |
Satellite Symposium: Emerging Approaches to Improve Medicine (Sponsored by Roche Applied Science) |
Room No. 9, 2F, ECEC |
October 23, 2009 (Friday) Evening |
18:00-20:00 |
Cocktail Party (Sponsored by Viva Biotech Ltd. ) |
|
October 24, 2009 (Saturday) Morning
|
08:30-12:10 |
Section 1-7: Molecular/Cell Biology and Drug Discovery |
Room No. 18, 2F, ECEC |
08:10-10:10 |
Section 1-8: Neurology and Drug Discovery |
Room No. 7, 2F, ECE |
08:30-10:10 |
Section 2-7: Novel Methods for Lead Modification |
Room No. 20, 2F, ECEC |
10:30-12:10 |
Section 2-8: Organometallic Chemistry in Drug Development |
08:30-12:10 |
Section 3-7: Cell-based to Tissue-based Assays |
Room No. 9, 2F, ECEC |
09:50-12:30 |
Section 3-14: Recent Advances in Drug and Gene Delivery |
Room No. 11, 2F, ECEC |
08:30-12:10 |
Section 5-6: Anti-Bacterial & Antifungal Drug Discovery (Part I) |
Room No. 12, 2F, ECEC |
08:20-11:30 |
Section 6-4: Cell Therapeutics and Regenerative Medicine |
Room No. 16, 2F, ECEC |
08:10-09:30 |
Section 7-2: Anti-Infectious Therapeutics |
Room No. 11, 2F, ECEC |
10:30-12:30 |
Section 7-3: Anti-Diabetes Therapeutics |
Room No. 7, 2F, ECE |
08:30-12:10 |
Section 8-1: Integrated Services & Partnership for Drug Discovery (Part I) |
Room No. 8, 2F, ECEC |
October 24, 2009 (Saturday) Afternoon
|
13:30-16:45 |
Section 1-9: Microbiology, Virology and Drug Discovery |
Room No. 7, 2F, ECEC |
15:30-17:50 |
Section 1-10: Hematology and Drug Discovery |
Room No. 11, 2F, ECEC |
13:30-16:45 |
Section 3-6: Cardiotoxicity / Hepatotoxicity and Drug Safety |
Room No. 20, 2F, ECEC |
13:30-15:10 |
Section 3-8: High Content Imaging (Sponsored by PerkinElmer Instruments ( Shanghai ) Co. Ltd) |
Room No. 11, 2F, ECEC |
13:30-17:10 |
Section 4-3: Translational Oncology |
Room No. 12, 2F, ECEC |
13:30-17:10 |
Section 5-2: Anti-Diabetes Drug Discovery |
Room No. 9, 2F, ECEC |
13:30-17:20 |
Section 5-7: Anti-Bacterial & Antifungal Drug Discovery (Part II) |
Room No. 16, 2F, ECEC |
13:30-17:30 |
Section 7-4: Anti-CNS Disorder Therapeutics |
Room No. 18, 2F, ECEC |
13:30-17:30 |
Section 8-4: Integrated Services & Partnership for Drug Discovery (Part II) |
Room No. 8, 2F, ECEC |
October 25, 2009 (Sunday) Morning |
08:30-11:45 |
Section 2-9: Improving ADME/DMPK Profile, Reducing DDI/Toxicity, and Overcoming Formulation Difficulties |
Room No. 18, 2F, ECEC |
08:30-12:10 |
Section 3-9: In Silico Models and Model Systems |
Room No. 12, 2F, ECEC |
08:30-12:10 |
Section 3-10: Nanotechnology and Novel Drug Delivery |
Room No. 11, 2F, ECEC |
08:30-11:40 |
Section 3-11: HPLC, LC-MS, Maldi-TOF and Structure Biology for Drug Discovery |
Room No. 16, 2F, ECEC |
08:30-10:10 |
Section 4-4: Translational Neurosciences |
Room No. 7, 2F, ECEC |
08:30-09:45 |
Section 5-8: Anti-HIV Drug Discovery |
Room No. 20, 2F, ECEC |
10:05-12:10 |
Section 5-9: Anti-HCV Drug Discovery |
Room No. 20, 2F, ECEC |
10:30-12:10 |
Section 5-10: Gastrointestinal Drug Discoveries |
Room No. 7, 2F, ECEC |
08:30-12:10 |
Section 5-11: Anticancer Drug Discovery (Part II) |
Room No. 9, 2F, ECEC |
08:10-12:15 |
Section 8-3: PK/PD and Bioanalysis Outsourcing Alliance |
Room No. 8, 2F, ECEC |
10/26-10/27/2009 (Monday, Tuesday) |
Tech Tour |
Hangzhou and Suzhou |
BIT' s Claims: All events BIT Life Sciences organized are purely for promotion of advancement of sciences and technologies for the sustainable development of a healthier and wealthier world. No political, religious racial bias and non-ethic knowledge are accepted through our intelligence exchange platform. Any illegal and offensive Information will be 100% avoided. |
|
|